We are continuing to evaluate shareholder value cr
Post# of 30028
Posted On: 09/02/2014 8:38:50 AM
Quote:
We are continuing to evaluate shareholder value creating arrangements for our diagnostics division, including a potential ‘spin-out’ or other business arrangements that would make strategic sense for the various LymPro and Amarantus stakeholders. We will not be giving additional details related to those possible arrangements in today’s business update call, as we are contractually prohibited from doing so.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼